167 related articles for article (PubMed ID: 36086966)
1. FUBP1 promotes the proliferation of lung squamous carcinoma cells and regulates tumor immunity through PD-L1.
Yu J; Peng W; Xue Y; Li Y; Yang L; Geng Y
Allergol Immunopathol (Madr); 2022; 50(5):68-74. PubMed ID: 36086966
[TBL] [Abstract][Full Text] [Related]
2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
3. High expression of PD-L1 mainly occurs in non-small cell lung cancer patients with squamous cell carcinoma or poor differentiation.
Liu LU; Xie B; Zhu W; He Q; Zhou J; Liu S; Tao Y; Xiao D
Oncol Res; 2023; 31(3):275-286. PubMed ID: 37305382
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of far upstream element-binding protein 1 (FUBP1) promotes tumor proliferation and unfavorable prognosis in tongue squamous cell carcinoma.
Chen Y; Liu J; Geng N; Feng C
Int J Biol Markers; 2020 Jun; 35(2):56-65. PubMed ID: 32339054
[TBL] [Abstract][Full Text] [Related]
5. Far upstream element-binding protein 1 is up-regulated in pancreatic cancer and modulates immune response by increasing programmed death ligand 1.
Fan P; Ma J; Jin X
Biochem Biophys Res Commun; 2018 Nov; 505(3):830-836. PubMed ID: 30301530
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma.
Koh YW; Han JH; Haam S; Lee HW
Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
[TBL] [Abstract][Full Text] [Related]
7. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
9. MiR-4652-5p Targets RND1 to Regulate Cell Adhesion and Promote Lung Squamous Cell Carcinoma Progression.
Zhou Y; Yan J; Chen H; Zhou W; Xiao G; Zou H; Yang J
Appl Biochem Biotechnol; 2022 Jul; 194(7):3031-3043. PubMed ID: 35334070
[TBL] [Abstract][Full Text] [Related]
10. GNA13 promotes the proliferation and migration of lung squamous cell carcinoma cells through regulating the PI3K/AKT signaling pathway.
Na J; Zhou W; Yin M; Hu Y; Ma X
Tissue Cell; 2022 Jun; 76():101795. PubMed ID: 35413491
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of VRK1 Inhibits Progression of Lung Squamous Cell Carcinoma through DNA Damage.
Du N; Zhang B; Zhang Y
Can Respir J; 2023; 2023():4533504. PubMed ID: 37547297
[TBL] [Abstract][Full Text] [Related]
12. Far upstream element-binding protein 1 (FUBP1) is a potential c-Myc regulator in esophageal squamous cell carcinoma (ESCC) and its expression promotes ESCC progression.
Yang L; Zhu JY; Zhang JG; Bao BJ; Guan CQ; Yang XJ; Liu YH; Huang YJ; Ni RZ; Ji LL
Tumour Biol; 2016 Mar; 37(3):4115-26. PubMed ID: 26490982
[TBL] [Abstract][Full Text] [Related]
13. microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.
Jiang K; Zou H
Bioengineered; 2022 Jan; 13(1):917-929. PubMed ID: 34968160
[TBL] [Abstract][Full Text] [Related]
14. Role of downregulated ADARB1 in lung squamous cell carcinoma.
Wang X; Ren X; Liu W; Chen X; Wei J; Gong Z; Yan Y; Xu Z
Mol Med Rep; 2020 Mar; 21(3):1517-1526. PubMed ID: 32016472
[TBL] [Abstract][Full Text] [Related]
15. eIF5B regulates the expression of PD-L1 in prostate cancer cells by interacting with Wig1.
Li Q; Xiao M; Shi Y; Hu J; Bi T; Wang C; Yan L; Li X
BMC Cancer; 2021 Sep; 21(1):1022. PubMed ID: 34525951
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3.
Liu W; Liu R; Yuan R; Wang X
Mol Biotechnol; 2021 Dec; 63(12):1268-1279. PubMed ID: 34386930
[TBL] [Abstract][Full Text] [Related]
17. Effects of Lipid Metabolism-Related Genes PTGIS and HRASLS on Phenotype, Prognosis, and Tumor Immunity in Lung Squamous Cell Carcinoma.
Lei K; Liang R; Tan B; Li L; Lyu Y; Wang K; Wang W; Wang K; Hu X; Wu D; Lin H; Wang M
Oxid Med Cell Longev; 2023; 2023():6811625. PubMed ID: 36703911
[TBL] [Abstract][Full Text] [Related]
18. MiR-139-3p Targets CHEK1 Modulating DNA Repair and Cell Viability in Lung Squamous Carcinoma Cells.
Zheng X; Zhang Y; Wu S; Jiang B; Liu Y
Mol Biotechnol; 2022 Jul; 64(7):832-840. PubMed ID: 35150405
[TBL] [Abstract][Full Text] [Related]
19. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056
[TBL] [Abstract][Full Text] [Related]
20. CircFOXK2 enhances tumorigenesis and immune evasion in non-small cell lung cancer by miR-485-5p/PD-L1 axis.
Zhang N; Fan J; Deng Z
Anticancer Drugs; 2022 Jun; 33(5):437-447. PubMed ID: 35324518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
